✦ LIBER ✦

Linagliptin , a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

✍ Scribed by Forst, Thomas; Pfützner, Andreas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Linagliptin, a xanthine-based dipeptidyl

✍ Deacon, Carolyn F; Holst, Jens J 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 314 KB

Pharmacokinetics, pharmacodynamics and t

✍ T. Heise; E. U. Graefe-Mody; S. Hüttner; A. Ring; D. Trommeshauser; K. A. Dugi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB

Safety and efficacy of the dipeptidyl pe

✍ Schernthaner, G.; Barnett, A. H.; Patel, S.; Hehnke, U.; von Eynatten, M.; Woerl 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

Efficacy, safety and dose-response relat

✍ Kadowaki, T.; Kondo, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Contributing factors related to efficacy

✍ Takashi Nomiyama; Yuko Akehi; Hiromasa Takenoshita; Ryoko Nagaishi; Yuichi Teraw 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 159 KB